Latest Biotech News

Revolution Medicines’ oral RAS inhibitor daraxonrasib (Rasonque) received FDA approval for metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy, marking the first...

AstraZeneca’s Wainua trial failure in transthyretin cardiac amyloidosis (ATTR-CM) has shifted scrutiny onto competing RNA-silencing approaches, according to the Stock/analysis coverage. As...

Biohaven outlicensed global rights to opakalim—a Kv7-targeting small molecule— to SK Biopharmaceuticals, with non-dilutive financing attached to Biohaven’s continued pipeline development. The...

A clinical comparison is underway via the Vision-FFR trial, which is testing whether vFFR derived from optical coherence tomography can match performance against traditional optical coherence...

The BEGONIA platform trial is evaluating durvalumab plus trastuzumab deruxtecan as a first-line regimen for HER2-low metastatic breast cancer, with the report highlighting unusually deep and...

Researchers report that IFI35 can block hepatitis B virus persistence by degrading HNF4α, a transcriptional regulator required for HBV cccDNA transcription. The study described IFI35 as part of an...

A study using AI radiographic analysis linked unfractionated heparin exposure in pregnancy to reduced maternal bone density, positioning routine chest X-ray data as an input for detecting skeletal...

A head-to-head comparison in the European Journal context reports that FAPI-04 PET/CT outperformed FDG in detecting recurrent breast cancer after surgery. The tracer targets fibrous...

A new report finds that while more than 90% of health systems have deployed third-party AI tools, fewer than half have the infrastructure to test and validate those systems before they are...

The FDA has cleared Protagonist Therapeutics and Takeda’s rusfertide (Mimrylo), a hepcidin mimetic, for adults with polycythemia vera (PV). The agency’s approval covers a weekly injection aimed at...

In the BEGONIA platform trial, durvalumab combined with trastuzumab deruxtecan (T-DXd) produced unusually deep and durable responses in women with HER2-low metastatic breast cancer as first-line...

Revolution Medicines’ oral RAS(ON) inhibitor daraxonrasib (Rasonque) received FDA approval for metastatic pancreatic ductal adenocarcinoma after prior systemic therapy or for patients not eligible...

A new economic analysis in Addiction Science & Clinical Practice estimated that preventing HIV among sexual and gender minorities with substance use disorders via Los Angeles County’s A.S.K.-PrEP...

The Vision-FFR trial is set to compare visual fractional flow reserve (vFFR) using angiography-derived techniques against optical coherence tomography (OCT)-based assessment in patients with...

An article highlights rapid progress in deploying AI to interpret medical images, with a new review focusing on deep learning approaches that connect imaging inputs with clinical decision-making....

A new pan-cancer single-cell atlas reports sex-biased macrophage interactions that appear to shape how immunotherapies perform. The study identifies SPP1+ macrophage crosstalk patterns that differ...

Trans-Pacific AusperBio has drawn $120M to advance an antisense oligonucleotide therapy (ASO) targeting chronic hepatitis B. The financing is positioned to support clinical development and...

Hydrogen-filled palladium nanosheets activated by light reportedly cleared Alzheimer’s amyloid plaques in mice and reduced oxidative stress markers in a preclinical study published in BMC...

A report finds hospitals have broadly adopted third-party AI tools, but testing and oversight infrastructure lags behind deployment at scale. The findings point to a mismatch between AI rollouts...

The U.S. FDA cleared Takeda’s hepcidin mimetic Mimrylo (rusfertide) for treatment of erythrocytosis in adults with polycythemia vera (PV), using phase 3 data already spotlighted in the drug’s...